Our Mission
The Oxford Vaccine Group has been at the forefront of vaccine development for 30 years, helping to fight diseases of major global importance through research and education around the world.
What's Happening?
30 Years of OVG
1994 - 2024
Join our celebrations and learn more about 30 years of ground-breaking vaccine research at the Oxford Vaccine Group.
Study Spotlight
| eclipse👤 18-49 or 60-80 years old 📅 Up to 5 or 9 visits over 31 days 💉 Group A: 1 vaccination and 1 inoculation. Group B: 1 vaccination 🧬 A study to understand how the body reacts to a combination of the flu virus and pneumococcal bacteria. 🪙 Up to £700 or £1060 reimbursement (dependent on group) |
Be a Vaccine Hero
Take part in a study
Could you be a Vaccine Hero by taking part in one of our clinical trials? Find out about the trials and studies currently looking for volunteers, as well as what it is like taking part from previous participants
Study - LEGACY02
A study examining lymph node cells to assess how age affects immune responses to a new vaccine.
Study - STELLAR
This study will compare the protective response to infections (also called an immune response) in the nose to the protective response in the blood following vaccination with a safe and effective nasal influenza vaccine
Study - MAGIC-01
A study of a new vaccine against Marburg Virus
Research at OVG
Education, Learning and Public Involvement
Latest Publications
⠀⠀⠀⠀⠀
-
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
Journal article
Qadri F. et al, (2024), Lancet, 404, 1419 - 1429
-
Oxford Vaccine Hesitancy Scale (OVHS): a UK-based and US-based online mixed-methods psychometric development and validation study of an instrument to assess vaccine hesitancy.
Journal article
Kantor J. et al, (2024), BMJ Open, 14
-
New programme to prevent bronchiolitis in infants
Journal article
Pollard AJ. et al, (2024), Archives of Disease in Childhood
-
Prevention of respiratory syncytial virus disease by immunisation.
Journal article
Benzaken TR. et al, (2024), Archives of disease in childhood. Education and practice edition
Working Together
National Immunisation Schedule Evaluation Consortium II
OVG is proud to lead NISEC II, a collaboration between a network of Academic Clinical Research groups and the UK Health Security Agency.
Immune Memory and Mechanisms of Protection from Vaccines
Oxford is proud to host the IMMPROVE consortium of universities, government, industry and others.
